Enabling Access to sp 3 ‐Enriched Targeted Protein Degraders via Redox‐Neutral Radical Cross‐Coupling
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.3989307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Philipp Neigenfind und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Scripps Research, San Diego, California, USA. Hauptthemen laut MEDLINE: Transcription Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: NIH HHS, National Science Foundation.
Abstract (Originalsprache)
Cullin‐RING Ligase 4 Cereblon (CRL4 CRBN )‐mediated targeted protein degradation (TPD) via cereblon (CRBN) E3 ligase modulatory drugs (CELMoDs) or ligand‐directed degraders (LDDs) represents a new modality in modern drug discovery. However, the CRBN‐binding portion of these degraders has been limited to flat, rigid architectures of conventional glutarimide scaffolds. This study presents a modular route to C3(sp 3 )–C(sp 3 ) linked glutarimides via a redox‐neutral cross‐coupling/palladium‐catalyzed hydrogenation sequence. This two‐step protocol is operationally simple, chemoselective, and broadly tolerant of diverse functional groups. It delivers sp 3 ‐rich, three‐dimensional scaffolds that access previously untapped chemical space. The resulting building blocks are ready for immediate use in the CELMoD and LDD arena and provide a versatile platform for next‐generation TPD design. Preliminary studies of BRD4‐targeting LDDs derived from C3(sp 3 )–C(sp 3 ) linked glutarimides demonstrate CRBN‐dependent degradation of BRD4, underscoring their translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Scripps Research, San Diego, California, USA.
- Discovery & Development Sciences, Bristol Myers Squibb Co, Princeton, New Jersey, USA.
ORCID-Profile: Clara Gathmann, Emily C Cherney, Christopher G Parker, Phil S Baran
Förderung
- NIH HHS
- National Science Foundation
Zitieren
APA
Neigenfind, P., Gathmann, C., Cherney, E. C., Parker, C. G., & Baran, P. S. (2026). Enabling Access to sp 3 ‐Enriched Targeted Protein Degraders via Redox‐Neutral Radical Cross‐Coupling. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.3989307
Vancouver
Neigenfind P, Gathmann C, Cherney EC, Parker CG, Baran PS. Enabling Access to sp 3 ‐Enriched Targeted Protein Degraders via Redox‐Neutral Radical Cross‐Coupling. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.3989307
BibTeX
@article{Neigenfind2026,
author = {Neigenfind, Philipp and Gathmann, Clara and Cherney, Emily C and Parker, Christopher G and Baran, Phil S},
title = {Enabling Access to sp 3 ‐Enriched Targeted Protein Degraders via Redox‐Neutral Radical Cross‐Coupling},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.3989307}
}
EUVIMED